HPHossein Pakdaman

Hossein Pakdaman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hossein Pakdaman has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Tau nuclear translocation is a leading step in tau pathology process through P53 stabilization and nucleolar dispersion

    by Shaqayeq Roqanian, Shahin Ahmadian, Seyed Masood Nabavi, Hossein Pakdaman, Mahshid Shafiezadeh, Ghazaleh Goudarzi, Koorosh Shahpasand

    Tau protein abnormalities are associated with various neurodegenerative disorders, including Alzheimer's disease (AD) and traumatic brain injury (TBI). In tau‐overexpressing SHSY5Y cells and iPSC‐derived neuron models of frontotemporal dementia (FTD), axonal tau translocates into the nuclear compartment, resulting in neuronal dysfunction. Despite extensive research, the mechanisms by which tau translocation results in neurodegeneration remain elusive thus far. We studied the nuclear displacement of different P‐tau species [Cis phosphorylated Thr231‐tau (cis P‐tau), phosphorylated Ser202/Thr205‐tau (AT8 P‐tau), and phosphorylated Thr212/Ser214‐tau (AT100 P‐tau)] at various time points using starvation in primary cortical neurons and single severe TBI (ssTBI) in male mouse cerebral cortices as tauopathy models. While all P‐tau species translocated into the somatodendritic compartment in response to stress, cis P‐tau did so more rapidly than the other species. Notably, nuclear localization of P‐tau was associated with p53 apoptotic stabilization and nucleolar stress, both of which resulted in neurodegeneration. In summary, our findings indicate that P‐tau nuclear translocation results in p53‐dependent apoptosis and nucleolar dispersion, which is consistent with neurodegeneration.


  • Open Access

    Migraine Headache as a Presenting Feature of Multiple Sclerosis: A Case Report

    by Mohammad Mahdi Rabiei, Zahra Cheraghi, Mahtab Ramezani, Hossein Pakdaman

    Multiple sclerosis (MS) is a chronic inflammatory disease, causing neuronal demyelination and axonal damage in the central nervous system. Symptoms of MS vary widely because of different grades of sensory, motor, and cognitive dysfunctions. Although headache as the initial symptom of MS is rare, it is a common comorbidity that affects most patients. However, it is unclear that the headache manifestation in newly diagnosed people with MS should be considered as an MS attack or merely a comorbid condition. We report the case of a 31-year-old woman with newly diagnosed MS who presented with exacerbation of headache episodes without any abnormal neurological exam findings. The headaches did not respond to nonsteroidal anti-inflammatory drugs and triptans. After administration of methylprednisolone, the headaches were significantly improved, and during 3 months of follow-up receiving glatiramer acetate, no episode of headache has occurred. This case demonstrates the possible relationship between migraine and MS in newly diagnosed patients. New-onset headaches, a change in the pattern of previous episodes, and inadequate clinical drug response to headache treatment should all be taken seriously and warrant further investigation. Thereby, early diagnosis and proper treatment for patients with MS could improve their quality of life.

  • Open Access

    Epilepsy lifetime prevalence in Iran: a large population- based national survey

    by Hossein Pakdaman, Ali Amini Harandi, Koroush Gharagozli, Farshid Alaeddini, Akram Esfandani, Seyed Hamidreza Mirbehbahani, Taher Doroudi, Pirhossein Kolivand, Parviz Bahrami, Hadi Kazemi

    Epilepsy has garnered increased public health focus because patients who suffer from epilepsy experience pronounced and persistent health and socioeconomic disparities despite treatment and care advances. The epidemiology of epilepsy is diverse in different countries and regions. This nationwide population-based cross-sectional study was conducted to determine the life time prevalence and health related factors of epilepsy for the first time in Iran through a two-phase door-to-door survey method. In phase I, a screening for epilepsy was performed on 68,035 people. Then in phase II, after the neurological evaluation of participants and reviewing medical records, 1130 subjects with epilepsy was confirmed. The life time prevalence of epilepsy was achieved to be 16.6 per 1000 people (95% CI 15.4–17.8) with the average age onset 19.1 ± 21.1 (active prevalence 9.5 per 1000 people). Focal seizure (59.3%), generalized epilepsy (38%) and unknown types of epilepsy (2.7%) were detected among participants. The overall life time prevalence of febrile convulsion was 4.1 per 1000 people. The frequency of attacks per year and per month were 3.0 ± 1.6 and 0.5 ± 0.1, respectively. Age-specific life time prevalence was highest among the age group of 15–19 years old [32.7 per 1000 persons (95% CI 29.1–36.8)] and it was higher in male (53.8%) than female (46.2%) participants. Our results showed that the life time prevalence of epilepsy in Iran is higher than worldwide average.